Viridian Therapeutics, Inc.\DEVRDNEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Fairmount Funds Management LLC | 17.95% | 15.6M | ▼ -0.69pp | 2024-09-17 |
| FMR LLC | 14.50% | 7.6M | — | 2024-01-10 |
| Deep Track Capital, LP | 9.90% | 5.4M | — | 2024-02-14 |
| BlackRock, Inc. | 6.50% | 3.4M | — | 2024-01-29 |
| The Vanguard Group | 5.71% | 3.0M | — | 2024-02-13 |
| Venrock Healthcare Capital Partners III, | 5.50% | 3.6M | ▼ -4.49pp | 2024-11-14 |
| Paradigm BioCapital Advisors LP | 4.60% | 3.5M | ▼ -5.39pp | 2024-11-14 |
| Perceptive Advisors LLC | 3.80% | 2.8M | ▼ -2.90pp | 2024-11-14 |
| Commodore | 3.70% | 1.9M | — | 2024-02-14 |
| STATE STREET CORPORATION | 3.20% | 2.4M | ▼ -1.95pp | 2024-10-18 |
| Venrock Opportunities Fund, L.P. | 2.90% | 1.9M | ▼ -2.30pp | 2024-11-14 |
| Biotechnology Value Fund, L.P. | 0.00% | 92.8K | — | 2024-02-14 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-03 | Jennifer Tousignant | Chief Legal Officer | Option exercise | 5.2K | — | — |
| 2026-03-03 | Beetham Thomas W. | Chief Operating Officer | Option exercise | 9.4K | — | — |
| 2026-03-03 | Mahoney Stephen F. | President and CEO | Option exercise | 18.4K | — | — |
| 2026-03-03 | Seth Harmon | Chief Financial Officer | Option exercise | 6.3K | — | — |
1–4 of 4